FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

$\sim$	AP	ᇚ	A١	/ N I

OMB Number:	3235-0287
Estimated average burder	n
hours per response:	0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Fishman Corey N.			2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Iterum Therapeutics plc</u> [ ITRM ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) C/O ITERUM THERAPEUTICS PLC		,	3. Date of Earliest Transaction (Month/Day/Year) 03/31/2023	X	Officer (give title below)  Chief Executive O	Other (specify below)			
FITZWILLIAM COURT, FL. 1, LEESON CLOSE  (Street)  DUBLIN 2  L2			4. If Amendment, Date of Original Filed (Month/Day/Year)	Individual or Joint/Group Filing (Check Applicable Lin     X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
(City) (State) (Zip)			Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

, (,	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transac Code (Ir 8)		4. Securities Ad Disposed Of (D			Securities Beneficially Owned	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price			

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (In 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Stock Option (Right to Buy)	\$1	03/31/2023		A		275,000		(1)	03/30/2033	Ordinary Shares	275,000	\$0.00	275,000	D	

## Explanation of Responses:

1. The shares underlying this option shall vest at a rate of 33.3% of the total number of shares on the one-year anniversary of March 31, 2023 and the remaining 66.7% will vest in equal monthly installments thereafter until March 31, 2026, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.

#### Remarks:

<u>/s/ Corey N. Fishman</u> <u>04/03/2023</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.